Healthcare provider profile · identity verified

Alexander Fiorentino

Internal Medicine · BATH, ME · NPI 1093246522

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	296	81
Losartan Potassium	Losartan Potassium	219	58
Lisinopril	Lisinopril	196	50
Levothyroxine Sodium	Levothyroxine Sodium	171	47
Omeprazole	Omeprazole	168	51
Amlodipine Besylate	Amlodipine Besylate	151	47
Rosuvastatin Calcium	Rosuvastatin Calcium	138	48
Hydrochlorothiazide	Hydrochlorothiazide	119	40
Metoprolol Succinate	Metoprolol Succinate	102	30
Gabapentin	Gabapentin	90	27
Albuterol Sulfate Hfa	Albuterol Sulfate	89	28
Duloxetine Hcl	Duloxetine Hcl	76	21
Lorazepam	Lorazepam	66	25
Fluoxetine Hcl	Fluoxetine Hcl	62	15
Metformin Hcl Er	Metformin Hcl	61	14
Sertraline Hcl	Sertraline Hcl	59	17
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	58	23
Simvastatin	Simvastatin	57	15
Trazodone Hcl	Trazodone Hcl	57	15
Furosemide	Furosemide	54	12
Tamsulosin Hcl	Tamsulosin Hcl	54	16
Oxycodone Hcl	Oxycodone Hcl	53	19
Bupropion Xl	Bupropion Hcl	50	16
Allopurinol	Allopurinol	49	14
Eliquis	Apixaban	46	15
Pantoprazole Sodium	Pantoprazole Sodium	46	14
Potassium Chloride	Potassium Chloride	42	13
Prednisone	Prednisone	39	27
Ozempic	Semaglutide	36	suppressed
Clonazepam	Clonazepam	35	suppressed
Alprazolam	Alprazolam	34	12
Escitalopram Oxalate	Escitalopram Oxalate	33	12
Metformin Hcl	Metformin Hcl	32	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	31	suppressed
Carvedilol	Carvedilol	29	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	29	suppressed
Montelukast Sodium	Montelukast Sodium	29	suppressed
Pregabalin	Pregabalin	29	11
Ezetimibe	Ezetimibe	27	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	17
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	11
Fluticasone Propionate	Fluticasone Propionate	24	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	24	12
Tramadol Hcl	Tramadol Hcl	24	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	23	20
Zolpidem Tartrate	Zolpidem Tartrate	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Glipizide	Glipizide	22	suppressed
Glipizide Er	Glipizide	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Jardiance	Empagliflozin	21	suppressed
Pravastatin Sodium	Pravastatin Sodium	21	suppressed
Rizatriptan	Rizatriptan Benzoate	21	suppressed
Estradiol	Estradiol	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	19	suppressed
Famotidine	Famotidine	19	suppressed
Synthroid	Levothyroxine Sodium	19	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	18	suppressed
Diazepam	Diazepam	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Prazosin Hcl	Prazosin Hcl	17	suppressed
Torsemide	Torsemide	17	suppressed
Valacyclovir	Valacyclovir Hcl	17	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	15
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	16	suppressed
Celecoxib	Celecoxib	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Finasteride	Finasteride	16	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Risperidone	Risperidone	16	suppressed
Azelastine Hcl	Azelastine Hcl	15	suppressed
Baclofen	Baclofen	15	suppressed
Cephalexin	Cephalexin	15	13
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Meloxicam	Meloxicam	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Dotti	Estradiol	14	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	14	suppressed
Meclizine Hcl	Meclizine Hcl	14	suppressed
Mounjaro	Tirzepatide	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	14
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Bevespi Aerosphere	Glycopyrrolate/Formoterol Fum	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Atenolol	Atenolol	12	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	suppressed
Colchicine	Colchicine	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	12	12
Farxiga	Dapagliflozin Propanediol	12	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	12	suppressed
Midodrine Hcl	Midodrine Hcl	12	suppressed
Clopidogrel	Clopidogrel Bisulfate	11	suppressed
Nystatin	Nystatin	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Spironolactone	Spironolactone	11	suppressed
Temazepam	Temazepam	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error